Rhabdomyosarcoma Stem Cell Therapy Development

Rhabdomyosarcoma is a cancerous tumor that develops from mesenchymal cells that differentiate into rhabdomyosarcoma cells or from rhabdomyosarcoma cells themselves. Stem cell therapy for rhabdomyosarcoma is currently being further explored. The understanding of the molecular mechanisms of rhabdomyosarcoma can facilitate the development of rhabdomyosarcoma stem cell therapies. CD BioSciences has launched a development service for rhabdomyosarcoma stem cell therapies, dedicated to advancing the treatment of this disease.

Signaling Pathways Involved in Rhabdomyosarcoma

Rhabdomyosarcoma (RMS) has two major molecular and histopathologic subtypes，including fusion-positive (FP) RMS. The understanding of tumor invasion and metastasis signaling pathways will help develop more effective therapies against rhabdomyosarcoma.

Signaling pathways involved in RMS metastasis. (Farah Ramadan. et al. 2020)

• RTK Signaling
  The receptor tyrosine kinase (RTK) fibroblast growth factor receptor 4 (FGFR4) is a highly expressed RTK in both RMS subtypes. In metastatic RMS tumors, FGFR4 transcript levels are elevated.
• Cytoskeletal Proteins
  Ezrin belongs to the family of proteins known as ezrin, radixin, and moesin (ERM). The c-Met RTK also targets Ezrin, which is upregulated in highly metastatic murine RMS compared to non-metastatic cell lines. Ezrin expression can be inhibited to lessen metastasis.
• G Protein and G Protein-coupled Receptors
  The G protein-coupled receptor cannabinoid receptor-1 (CNR1), whose expression is linked to increased metastatic potential and basement membrane invasion of FPRMS cells in vitro, is upregulated in FPRMS tumors.
• Hedgehog Signaling Pathway
  Hedgehog (Hh) signaling is particularly connected to FNRMS in RMS. Hh signaling inhibition decreases both phenotypes, while Hh signaling activation increases ERMS self-renewal and invasive capacity.
• Notch Pathway
  Gamma-secretase must release the Notch intracellular domain in order for the Notch pathway to be activated. In vitro RMS invasion and motility significantly decreased after gamma-secretase inhibition, suggesting a potential role in mediating RMS cells' invasive behavior.
• Wnt signaling pathway
  Studies show that canonical Wnt signaling is inactive in RMS, despite the fact that canonical Wnt signaling is crucial for the differentiation of skeletal muscle. In mice with a p53 deletion, silencing the transcription factor c-fos encourages the growth of RMS with highly invasive characteristics by preventing Wnt signaling.

Advances in Stem Cell Therapy for Rhabdomyosarcoma

Currently, RMS is treated almost exclusively with local therapies (surgery or radiotherapy) as well as chemotherapy. Patients with severe disease require high-dose chemotherapy for rhabdomyosarcoma and stem cell transplantation to improve survival. In addition, stem cells have a natural tendency to metastasize to tumors and therefore can be used as drug delivery vehicles. The use of stem cells for targeted therapy holds significant promise for application.

Our Services

CD BioSciences offers rhabdomyosarcoma stem cell therapy development services. We have a mature experimental process and professional experimental skills. We have a professional R&D team and a mature experimental system. Based on our professional laboratory team, we can contribute to the development of stem cell therapy for rhabdomyosarcoma.

As a pioneer in biotechnology, CD BioSciences has grown into one of the largest independent biotechnology companies in the world. CD BioSciences is committed to providing professional and efficient service to our customers around the world. If you are interested in our service, please contact us.

Reference

1. Farah Ramadan. et al. (2020). Signaling pathways in Rhabdomyosarcoma invasion and metastasis. Cancer Metastasis Rev. 39(1):287-301.